KRAS and neoplasm: Despite the importance of these processes at a cellular level, the net fate of glutamine as it pertains to an entire tumor is variable and relies on a multitude of factors such as tissue type, specific cellular make-up within a tumor (including immune, stromal, endothelial and cancer cells) and the presence or absence of specific genetic lesions such as mutations in critical proteins such as c-Myc or KRAS.